Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint
June 29, 2015 at 08:31 AM EDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the ...
